GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Dividend-Payout-to-FFO

ANL (Adlai Nortye) Dividend-Payout-to-FFO


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Adlai Nortye Business Description

Traded in Other Exchanges
N/A
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.